Welcome to our dedicated page for Ainos news (Ticker: AIMD), a resource for investors and traders seeking the latest updates and insights on Ainos stock.
Ainos, Inc. (NASDAQ: AIMD) is a dual-platform AI and biotech company whose news flow is centered on its AI Nose SmellTech platform and related AI infrastructure, alongside development of its low-dose oral interferon candidate, VELDONA. Company updates frequently highlight progress in digitizing scent into Smell ID, expanding industrial deployments, and advancing its Smell Language Model (SLM) through its subsidiary ScentAI Inc.
On this page, readers can follow AIMD news related to industrial partnerships, commercialization milestones, and strategic agreements. Recent announcements have covered distribution and deployment partnerships in semiconductor front-end manufacturing, collaborations with industrial computing and edge AI providers, and expansion of AI Nose pilots across smart factories, robotics, and healthcare environments. Ainos also issues press releases on its GICS reclassification into the technology sector, intellectual property additions, and SmellTech-as-a-Service contracts.
Investors and observers can expect news items on topics such as multi-year SmellTech-as-a-Service agreements, pilot deployments in senior care and robotics, new patents for AI Nose and digital olfaction, and updates on the company’s platform strategy to separate sensing hardware (Ainos) from AI intelligence (ScentAI). Financial result releases and associated commentary provide additional context on research and development priorities and commercialization roadmaps.
By monitoring this news feed, users gain a consolidated view of how Ainos is building its SmellTech ecosystem across semiconductors, industrial automation, robotics, and healthcare, while continuing to develop its VELDONA oral interferon program. Bookmark this page for ongoing coverage of AIMD press releases, partnership announcements, and regulatory communications.
Ainos (NASDAQ:AIMD) is expanding its AI Nose technology from healthcare into robotics and semiconductor manufacturing, according to a new Water Tower Research report. The company's proprietary technology digitizes scent into Smell IDs using MEMS sensors and AI models, achieving nearly 80% accuracy across 22 VOC types in semiconductor settings and over 90% accuracy in women's health applications.
The company has secured strategic partnerships in Japan with a service robot company for integration into robots operating in office buildings, data centers, and public infrastructure. Additionally, Ainos is collaborating with the world's largest semiconductor packaging and testing company for smart factory initiatives.
The company's execution timeline includes: mass production of elderly care products in 1H 2025, pilot deployment in robotics and semiconductor factories in 2H 2025, and industrial projects scaling commercially in 2026. These initiatives target the e-nose market, projected to reach $76.5B by 2032, and the robotics market, expected to reach $178.6B by 2030.
Ainos (NASDAQ:AIMD), a pioneer in AI-powered scent digitization, has announced its participation in an upcoming fireside chat with Water Tower Research (WTR) scheduled for April 8, 2025, at 10:00 a.m. ET.
The discussion will feature WTR's senior research analyst Do Kim and managing director John Roy. During the session, Ainos will explore various aspects of their AI Nose technology, including:
- Applications in smart manufacturing and robotics
- Impact of AI-driven digitized smell beyond healthcare
- Recent collaboration programs in robotic and semiconductor manufacturing
- Technological advancements in training AI's digital olfaction
- Market opportunities across different industries
The event will be listen-only, with a replay available on Ainos' investor relations website.
Ainos (NASDAQ:AIMD) has formed a strategic partnership with Advanced Semiconductor Engineering (ASE), the world's largest semiconductor packaging and testing services provider, as highlighted in a new Water Tower Research report. The collaboration will integrate Ainos' AI Nose technology into ASE's factories.
The AI-powered electric nose technology has previously demonstrated nearly 80% accuracy in detecting 22 VOCs in Japanese semiconductor facilities. This partnership follows Ainos' recent collaboration with ugo, Inc. to create the first robots with smell capabilities.
ASE, operating under ASE Technology Holding Co. with a $21 billion market cap and $19 billion in FY24 revenue, runs 46 lights-out factories and employs over 700 automation engineers. The partnership will initially focus on optimizing AI Nose for semiconductor packaging and testing environments, followed by plans for large-scale deployment within ASE facilities and exploration of broader industrial applications.
Ainos (NASDAQ:AIMD) has announced a strategic partnership with Advanced Semiconductor Engineering (ASE) to implement AI-powered scent digitization in semiconductor manufacturing. The collaboration will integrate Ainos' patented AI Nose technology, which analyzes airborne chemicals into 'Smell IDs', into ASE's smart factories.
The AI Nose technology has demonstrated nearly 80% accuracy in identifying 22 different VOCs in Japanese semiconductor facilities. The system will enable real-time air quality monitoring, predictive maintenance, process optimization, and enhanced ESG compliance across ASE's 46 fully automated factories.
Under a legally binding MOU, the partnership aims to:
- Refine VOC detection for semiconductor environments
- Plan large-scale AI Nose deployment across ASE operations
- Explore broader industrial applications
Ainos (NASDAQ:AIMD) reported its fiscal year 2024 financial results, marking a transition from COVID-19 testing to advancing VELDONA® and AI Nose programs. The company's AI Nose program achieved up to 94% accuracy in clinical trials for women's health testing, while its VOC detection platform showed 80% accuracy in semiconductor applications.
Financial highlights include:
- Revenue declined to $20,729 in 2024 from $122,112 in 2023
- Net loss increased to $14.86M from $13.77M in 2023
- Cash position improved to $3.89M from $1.89M year-over-year
- R&D expenses rose to $8.41M from $7.32M
- SG&A expenses decreased to $5.40M from $5.64M
Key developments include a partnership with Taiwan Tanabe Seiyaku for VELDONA® manufacturing and IRB approval for Sjögren's syndrome clinical trials. The company plans to commence second-generation Ainos Flora clinical studies in H1 2025 and aims to submit IND applications to the FDA by H2 2025.
Ainos (NASDAQ:AIMD) has formed a strategic partnership with ugo Inc., a leading Japanese service robotics company, to integrate AI Nose technology into service robots. The collaboration, highlighted in a Water Tower Research report, marks a breakthrough in digitizing olfactory sensing.
The partnership aims to enhance robotic capabilities across industrial safety, public security, environmental monitoring, and healthcare. ugo, which leads Japan's service robot market share, deploys its robots in commercial buildings, data centers, factories, and public facilities.
The integration represents a significant advancement in robotics, adding smell capability to existing features like collision detection, AI-powered image recognition, and environmental sensing. Commercial deployment is expected by 2026, targeting the Japanese market, which accounts for 38% of worldwide robot production. The service robot market in Japan is projected to reach $1.2 billion by 2025, part of a $40.6 billion global market.
Ainos (NASDAQ:AIMD) and ugo, Japan's largest service robot company, announced a strategic partnership to develop the world's first smell-enabled robots by integrating Ainos' AI Nose technology with ugo's autonomous robotic platform.
The AI Nose technology, initially developed for medical diagnostics, has demonstrated nearly 80% accuracy in identifying 22 different volatile organic compounds (VOCs) in Japanese semiconductor facilities. The integration will enable robots to:
- Detect gas leaks and toxic chemicals in manufacturing plants
- Identify explosives and hazardous substances for public safety
- Monitor air quality and pollutants
- Analyze VOC samples for disease detection
The partnership will explore revenue opportunities through technology licensing, Robotics-as-a-Service (RaaS), cloud-based scent intelligence, and maintenance services. The development plan includes technology integration, pilot deployments, AI optimization, and global commercialization.
Ainos (NASDAQ:AIMD) has secured a significant Japanese patent (No. 7619659) for VELDONA®, its innovative oral interferon formulation designed to treat and prevent coronavirus infections. This follows a recent patent approval in Taiwan, strengthening the company's global IP portfolio in a market projected to exceed $16 billion by 2031.
The patent includes 15 key claims covering VELDONA's formulation, featuring low-dose administration under 1,000 IU, sublingual and buccal delivery mechanisms, and flexible dosage forms. Unlike traditional interferon therapies, VELDONA® doesn't require cold chain logistics, significantly reducing costs.
The technology offers dual benefits for coronavirus treatment and prevention, with proven broad-spectrum antiviral efficacy against multiple variants. VELDONA® addresses accessibility through non-invasive oral therapy, affordability by eliminating cold chain dependency, and enhanced safety through its low-dose formulation.
Ainos (NASDAQ:AIMD) received a Water Tower Research report highlighting its AI Nose technology developments and strategic milestones. The report focuses on four key areas: robotics integration, where Ainos seeks partnerships to enhance robot functionality with olfactory capabilities; smart manufacturing, achieving 80% accuracy in identifying 22 VOCs across 761 semiconductor factory samples, with mass production planned for 1H2025; elderly care monitoring in Japan, developing an AI-driven telehealth system for long-term care facilities; and women's health testing through Ainos Flora device, which showed 94% accuracy in detecting vaginal infections and STIs.
The report also covers VELDONA® clinical trials, scheduled to begin in 1H25 for Sjogren's syndrome and HIV-related oral warts in Taiwan, with completion expected in 2026. Animal health trials for FCGS are set to complete in 1H25, with U.S. IND applications planned for 2H25.
Ainos (NASDAQ:AIMD) has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement. The company was initially notified on July 15, 2024, that its stock price had been trading below the required $1.00 minimum for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). After the initial 180-day compliance period ending January 13, 2025, Nasdaq has granted Ainos an additional extension until July 14, 2025 to meet the minimum bid requirement.
The company's shares will continue to trade on the Nasdaq Capital Market during this extension period, with no immediate effect on its listing status.